Array BioPharma Inc.

Array BioPharma Inc.

Array BioPharma Inc.

Overview
Date Founded

1998

Headquarters

3200 Walnut Street, Boulder, CO, 80301, USA

Type of Company

Public

Employees (Worldwide)

51 - 100

Industries

Pharmaceuticals
Medical Support Services
Hospitals & Patient Services
Biotechnology

Company Description

Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO.

Contact Data
Trying to get in touch with decision makers at Array BioPharma Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Co-Founder

President, Treasurer & Director

Chief Financial Officer & Chief Accounting Officer

Chief Operating Officer

Interim General Counsel

Chief Scientific Officer

Director-Corporate Communications & Investor

Secretary, Director & Chief Governance Counsel

Board of Directors

President, Treasurer & Director at Array BioPharma Inc.

In-House Counsel at Pfizer, Inc.

Senior Vice President, Corporate Secretary & Chief Governance Counsel at Pfizer, Inc.

Paths to Array BioPharma Inc.
Potential Connections via
Relationship Science
You
Array BioPharma Inc.
Recent Transactions
Details Hidden

Pfizer, Inc. purchases Array BioPharma Inc.

Details Hidden

Array BioPharma Inc. issued . USD Common Stock

Details Hidden

Array BioPharma Inc. issued USD Common Stock

Transaction Advisors
Auditor

Advised onArray BioPharma Inc. issued . USD Common Stock

Escrow Agent

Advised onArray BioPharma Inc. issued . USD Common Stock

Underwriter

Advised onArray BioPharma Inc. issued . USD Common Stock

Legal Advisor

Advised onArray BioPharma Inc. issued . USD Common Stock

Underwriter

Advised onArray BioPharma Inc. issued . USD Common Stock

Managing Director

Advised onArray BioPharma Inc. issued USD Common Stock

Advisors & Consultants
Advisor

Chief Financial Officer at OnKure, Inc.

Consultant

Co-Founder at Array BioPharma Inc.

Advisor

General Counsel & Corporate Secretary at Peloton Therapeutics, Inc.

Clients

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1998 and is headquartered in Bothell, Washington.

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Key Stats and Financials As of
Market Capitalization
$10.3B
Total Enterprise Value
Earnings Per Share
Non-Profit Donations & Grants
Investments
Details Hidden

Loxo Oncology, Inc. is a biopharmaceutical company, which engages in the development of small molecule therapeutics for the treatment of cancer. It focuses on genetic alterations, targeted therapies, and genetic testing. The company was founded by Joshua H. Bilenker in May 2013 and is headquartered in Stamford, CT.

Investors
Details Hidden

Venture Partner at OrbiMed Advisors LLC

Details Hidden

Co-Founder at Chemizon, Inc.

Details Hidden

Co-Founder at Array BioPharma Inc.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Array BioPharma Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Array BioPharma Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Array BioPharma Inc..